

27-Hydroxycholesterol induces expression of zonula occludens-1 in monocytic cells via multiple kinases pathways

Hyok-rae Cho

Department of Neurosurgery, College of Medicine, Kosin University

Bo-Young Kim

Department of Pharmacology, School of Medicine, Pusan National University

Koanhoi Kim

Department of Pharmacology, School of Medicine, Pusan National University

Dongjun Lee

Department of Convergence Medicine, School of Medicine, Pusan National University

Seong-Kug Eo

College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University

Yonghae Son (✉ squall0211@hanmail.net)

Department of Pharmacology, School of Medicine, Pusan National University

Research Article

Keywords: cell differentiation, 27-hydroxycholesterol, monocytes, tight-junction protein, zonula occludens-1

Posted Date: February 23rd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1322403/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Zonula occludens (ZO)-1, a tight-junction protein (TJP), is expressed in dendritic cells (DCs) but not in monocytes, and 27-hydroxycholesterol (27OHChol) drives the differentiation of monocytes into DCs. Because the effects of 27OHChol on ZO-1 are not yet clearly defined, we investigated whether 27OHChol induces expression of the TJP. The treatment of human THP-1 monocytic cells with 27OHChol resulted in the elevated transcript levels of ZO-1 but not of ZO-2 or -3. 27OHChol increased the total amount of ZO-1 protein in the cells as well as its level on the cells surface. Cholesterol, however, did not influence expression of ZO-1. And, the expression of ZO-1 protein was mediated by endoplasmic reticulum (ER)-to-Golgi body transport system. Pharmacological kinase inhibition with LY294002 (a PI3K inhibitor), U0126 (a MEK/ERK inhibitor), or PP2 (a Src family kinase inhibitor) resulted in impaired ZO-1 expression at both transcript and protein levels. Drugs that are reported to suppress DC differentiation also inhibited 27OHChol-mediated expression and the localization of ZO-1, indicating the coincidence of ZO-1 upregulation and DC differentiation. These results suggest that ZO-1 is differentially expressed while monocytes differentiate into DCs in the presence of 27OHChol via pathways in which distinct signaling molecules are involved.

Introduction

Zonula occludens-1 (ZO-1), a type of tight-junction protein (TJP), serves as a scaffold protein to assemble integral membrane proteins, actin cytoskeletons, and cytosolic proteins in tight junctions (TJs) (1, 2). Levels of ZO-1, which is constitutively expressed in almost tissues and several adherent cell types including endothelial cells and smooth muscle cells (3, 4), are altered depending on cell conditions, cell density, or differentiation. Dendritic cells (DCs), but not monocytes, express TJPs including ZO-1 (3), and ZO-1 expression can be induced during this differentiation into dendritic cells. DCs differentiated from THP-1 monocytic cells using cytokines (IL-4, GM-CSF, and TNF- α) express TJPs including ZO-1, occludin, and JAM-A (4). These findings suggest that levels of ZO-1 increase in response to exogenous stimuli promoting DC differentiation.

Oxysterols are cholesterol metabolites that are generated via enzymatic or non-enzymatic oxidation. The most abundant oxysterol in human blood is 27-hydroxycholesterol (27OHChol), followed by 7-oxygenated cholesterol molecules such as 7-ketocholesterol (7K), 7 α -hydroxycholesterol (7 α OHChol), and 7 β -hydroxycholesterol (7 β OHChol) (5). The oxysterols not only can induce cell differentiation into either macrophages or DCs but also are involved in ZO-1 expression. 7 α OHChol and 27OHChol induce the differentiation of monocytes into DCs displaying a mature phenotype (6–9), and 7K induces macrophage differentiation (10). All three 7-oxygenated cholesterol derivatives (such as 7 α OHChol, 7 β OHChol, and 7K) decrease the ZO-1 levels in vascular smooth muscle cells, whereas 7 α OHChol alone induces its expression in monocytic cells (11), indicating the regulation of ZO-1 in the presence of a specific type of oxysterol. However, despite the fact that it is the most abundant oxysterol in vivo, it is unknown whether 27OHChol affects the levels of ZO-1.

In the present study, we examined the effects of 27OHChol on the expression and localization of ZO-1. We also attempted to determine the signaling pathways involved and investigated the association of ZO-1 expression with DC differentiation.

Materials And Methods

Cell culture and reagents

THP-1 cells purchased from the American Type Culture Collection (cat. no. TIB-20; ATCC, Manassas, VA, USA) were maintained in RPMI 1640 containing 10% fetal bovine serum (FBS) in the presence of penicillin and streptomycin. Brefeldin A (BFA) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Pierce™ Cell Surface Protein Isolation Kit was purchased from Thermo Scientific (IL61101, USA). Membrane protein was harvested using Cholesterol and 27OHChol were purchased from Sigma-Aldrich and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively, and dissolved in ethanol. Antibodies against ZO-1 and β -actin were purchased from Santa Cruz Biotechnology. Alexa Fluor 488-conjugated secondary antibodies for FACS analysis and immunofluorescence were purchased from Invitrogen (Eugene, Oregon, USA). Reagents for reverse transcription were purchased from Promega Corporation (Madison, WI, USA).

Reverse transcriptase and real-time polymerase chain reaction (RT and real-time PCR)

Total RNA was reverse transcribed at 42°C for 1 h using 100 U Moloney Murine Leukemia Virus reverse transcriptase in a 10- μ L reaction volume containing 50 mM Tris-HCl (pH 8.3 at 25°C), 55 mM KCl, 3 mM MgCl₂, 10 mM DTT, 1 μ g oligo dT 15 primers, 0.125 mM each dNTP, and 40 U RNase inhibitor.

Subsequent qPCR was performed following a previously described protocol (13). Each 20- μ L reaction mixture consisted of 10- μ L SYBR Green Master Mix, 2- μ L gene-specific forward and reverse primers (10 pM each), and a cDNA template. The thermal cycling conditions were: 95°C for 10 min, followed by 45 cycles of 95°C for 10 s, 50°C for 10 s, and 72°C for 10 s. Primer sequences for the real-time PCR were as follows. ZO-1: 5'- ccagcatcatcaacctctgc (forward) and 5'- catgcgacgacaatgatggt (reverse), ZO-2: 5'- agccccgagaacttttcttc (forward) and 5'- ctcttgaatgccagcaaca (reverse), ZO-3: 5'- catccaggaggagatcaga (forward) and 5'- ccagaaaatgtcctgcttcc (reverse), and GAPDH: 5'- atggggaaggatgaaggtcg (forward) and 5'- ggggtcattgatggcaacaata (reverse).

Western blot analysis

Cells were lysed with lysis buffer (PRO-PREP™, iNtRON Biotechnology, Daejeon, Korea) containing a protease inhibitor cocktail (Sigma-Aldrich). Proteins in the lysates were separated by SDS-PAGE and transferred onto PVDF membranes. After incubating for 1 h with 5% skim milk in 0.1% Tween 20/TBS to block the non-specific binding of primary antibodies, the membranes were probed with specific primary antibodies at 4°C overnight. After three washes with the wash buffer (0.1% Tween 20/TBS) for 15 min each, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room

temperature. Membranes were then washed a further three times using the wash buffer for 15 min each, and bands were detected using the PIERCE® enhanced chemiluminescence (ECL) Western blotting detection system (Thermo Scientific, IL, USA). Chemiluminescence images were captured using an Amersham Imager 600 (GE Healthcare Life Sciences, Pittsburgh, PA, USA).

Immunofluorescence

THP-1 cells were seeded on cover slips and stimulated for 48 h with cholesterol or 27OHChol. The cells were fixed for 20 min with 1% paraformaldehyde and incubated for 1 h with a blocking solution of 5% skim milk in PBS. After incubating for 2 h with the primary antibody against ZO-1 diluted in the blocking solution (1:100) at room temperature, the cells were washed twice for 5 min each using PBS. Following incubation for 1 h with secondary antibodies diluted in PBS (1:200) at room temperature in the dark, the cells were washed using PBS. The cover slips were mounted, and the cells were visualized using a confocal microscope (FV1000; Olympus Cor., Tokyo, Japan).

Flow cytometric analysis

After harvesting by centrifugation at $200 \times g$ for 5 min at room temperature, both treated and untreated THP-1 cells were incubated for 2 h with anti-ZO-1 antibodies diluted to 1:100 in FACS buffer (2 mM EDTA and 0.2% BSA in PBS). The cells were washed with cold PBS and incubated for 1 h with fluorescent dye-conjugated secondary antibodies diluted to 1:200 in FACS buffer at 4°C. After washing with cold PBS, the cells were resuspended in 1% paraformaldehyde in PBS. Subsequently, the cells were analyzed using a flow cytometer (FACS CANTO II; BD Company, NJ, USA).

Statistical analysis

Statistical analyses were performed using one-way ANOVA, followed by Tukey's multiple comparison tests, using GraphPad Prism (version 5.0; GraphPad software Inc., CA, USA).

Results

Effects of 27OHChol on ZO-1 expression in monocytic cells

To examine whether 27OHChol affected the ZO-1 levels in monocytes, we analyzed the expression of ZO family transcripts using RT-PCR and quantitative real-time PCR in THP-1 cells. Among the ZO-1 family, 27OHChol elevated the transcript levels of ZO-1, but not of ZO-2 or -3, and cholesterol did not influence any ZO-1 family transcript levels (Fig. 1A and supplementary data 1). In agreement with the results of the RT-PCR and real-time PCR, levels of ZO-1 protein increased with 27OHChol treatment, but not with cholesterol (Fig. 1B). The percentage of cells expressing ZO-1 on the surface increased from 2.7–18.7% following treatment with 27OHChol. Cholesterol, however, did not alter the ZO-1 immunoreactivity of the cells (Fig. 1C). We also determined the localization of ZO-1. The immunoreactivity of ZO-1 protein was localized on the cell surface, as visualized via confocal microscopy (Fig. 1D). These results suggest that ZO-1 protein is upregulated in the presence of 27OHChol.

We investigated the effects of 27OHChol concentrations on ZO-1 levels. Expression of ZO-1 increased in a dose-dependent manner upon treatment with 27OHChol. 27OHChol, up to a concentration of 2.5 µg/ml, elevated the transcript (Fig. 2A), protein (Fig. 2B), and immunoreactivity levels of ZO-1 (Fig. 2C). We also determined the time-course effects of 27OHChol. The ZO-1 transcripts and protein levels and ZO-1 immunoreactivity on the cell surface reached maximum levels after 48 h of treatment with 27OHChol and decreased thereafter (Fig. 3A-C).

Involvement of endoplasmic reticulum (ER)-Golgi-transport in ZO-1 expression

We investigated roles of the ER-to-Golgi transport system in the expression of ZO-1 by using BFA. The level of ZO-1 protein on monocytic cells, which was induced by 27OHChol, was downregulated by the treatment with BFA (Fig. 4A). BFA, however, did not affect the transcript levels of ZO-1 (data not shown). The immunoreactivity of ZO-1 (green) detected on cell surface after stimulation with 27OHChol was reduced by BFA (Fig. 4B). These results indicated that ZO-1 protein is transported onto cell surface of monocytes via by the ER-to-Golgi transport system.

Involvement of multiple protein kinases in ZO-1 expression

Multiple signaling pathways have been demonstrated to play roles in the cellular effects of 27OHChol. In this study, we investigated the involvement of the PI3K, ERK, and Src pathways in ZO-1 expression using specific inhibitors. An increase in the ZO-1 transcript levels was blocked in the presence of LY294002 (an inhibitor of PI3K) and U0126 (an inhibitor of MEK/ERK). PP2 (an inhibitor of the Src kinase family) also impaired the transcription of ZO-1 (Fig. 5A). In agreement with the RT-PCR and real-time PCR data, the levels of ZO-1 protein in the cells and on the cell surface were lowered in the presence of kinase inhibitors (Fig. 5B, 5C and D). We suggest that the inhibitory effects of the kinase inhibitors were not due to cytotoxicity because none of them decreased the cell viability (supplementary data 2A). These results imply that the PI3K, ERK, and Src kinase pathways are necessary for 27OHChol to induce expression of ZO-1.

Effects of drugs suppressing DC differentiation on ZO-1 expression

DC differentiation was suppressed by drugs such as cyclosporine A (CsA), diclofenac (Df), and dexamethasone (Dx) (8, 12, 13). Therefore, we investigated the correlation between ZO-1 and DC differentiation by assessing the effects of these drugs on ZO-1 expression. The levels of ZO-1 transcripts, which were elevated following stimulation with 27OHChol, decreased in the presence of Dx (Fig. 6A). In agreement with the results of the RT-PCR and real-time PCR, Dx also suppressed the expression of ZO-1 protein (Fig. 6B). The expressed ZO-1 protein was confirmed using flow cytometry (Fig. 6C). The percentage of ZO-1 expression on the cell surface increased from 2.8–21.9% following treatment with

27OHChol, and this was reduced to 1.4%, 1.0%, and 1.0% by 0.01, 0.1, 1 μ M of Dx, respectively. When visualized, ZO-1 protein (green fluorescence) was localized on the surface after stimulation with 27OHChol, but the fluorescence was barely detected in the presence of Dx (Fig. 6D). CsA and Df also affected the 27OHChol-induced expression of ZO-1 at transcript and protein levels (supplementary data 3). The three drugs did not cause cytotoxicity at the concentrations that impaired expression of ZO-1 (supplementary data 2B). These results suggest that expression of ZO-1 coincides with DC differentiation in a milieu in which 27OHChol is abundant.

Discussion

In this study, we demonstrated the increased expression of ZO-1 alone in monocytic cells following exposure to 27OHChol, indicating an induction of ZO-1 in response to an extracellular stimulus of oxidized cholesterol. ZO proteins, comprising ZO-1, ZO-2, and ZO-3, are ubiquitous scaffolding proteins. They are co-localized at junctional sites and can bind with themselves via the PDZ2 domain (14). They display overlapping, but distinctive, expression patterns. ZO-1 is expressed at cell junctions of cardiac myocytes, but ZO-2 is not expressed in the heart (15). ZO-2 and ZO-3 are concentrated in epithelial and endothelial tight junctions (14, 16). Although they share functional and structural similarities, ZO proteins display differential regulation and functions under hypercholesterolemic circumstances.

Besides the specific association of ZO-1 with tight junctions, it is involved in the regulation of the cell cycle. This protein has been detected in the nucleus during the proliferation of epithelial cells (17, 18). ZO-1 binds with ZO-1-associated nucleic acid-binding protein (ZONAB), promoting cell proliferation. ZO-1 functions as a suppressor of ZONAB and controls the accumulation of ZONAB in the nucleus by cytoplasmic sequestration; the overexpression of ZO-1 results in reduced nuclear ZONAB accumulation and proliferation (16, 18). We demonstrated that ZO-1 induced in the presence of 27OHChol is mainly localized on the cell surface. Collectively, these findings suggest that ZO-1 may regulate proliferation by sequestering the proteins involved in proliferation in the cytoplasm, in the presence of 27OHChol.

ZO proteins are multi-domain scaffolds that bind directly to various types of proteins, in addition to having scaffolding functions in organizing gap junction complexes, via the PDZ (PSD-95/Discs-large/ZO-1) domain, SH3 domain, and guanylate kinase domain (14). ZO-1 can bind with protein kinases in the cytoplasm. After binding with the serine/threonine-protein kinase MRCK β , the ZO-1/MRCK β complex regulates migration at the leading edge of migrating cells (19). Monocytic cells exposed to 27OHChol differentiate into DCs, which can migrate to inflammatory regions where they accelerate immune responses (7). We demonstrated that CsA, Df, and Dx impair the ZO-1 expression induced by 27OHChol, and these drugs are well known for their anti-inflammatory and immunosuppressive effects (8, 12, 13). Furthermore, the PI3K, ERK, and src kinases play crucial roles in migration (20–22). Therefore, the results of this study suggest the possibility that the upregulated ZO-1 protein may be involved in cell migration, via interactions with protein kinases during inflammation or immune responses.

In summary, we demonstrated that 27OHChol upregulates ZO-1 using ER-to-Golgi body transport system via PI3K, ERK, and src in monocytic cells, which is impaired by the drugs suppressing DC differentiation. These results also cause us to question the biological functions of the upregulated protein. Further investigations are needed to understand whether ZO-1 plays roles in migration and the regulation of cell proliferation during the process of DC differentiation.

Declarations

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgments

This research was supported by the Basic Science Research Program, through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2016R1C1B1013443 and NRF-2019R111A3A01055344).

Author contributions

Y. Son and B.-Y. Kim performed the experiments. Y. Son, H.-R. Cho, and K. Kim designed the study. Y. Son, B.-Y. Kim, D. Lee, S.-K. Eo, and K. Kim analyzed and interpreted the data. Y. Son, D. Lee, H.-R. Cho, and K. Kim drafted the manuscript. All authors discussed the results and contributed to the final manuscript.

Availability of Data and Materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

References

1. N. Ide *et al.*, Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells. *Oncogene* **18**, 7810–7815 (1999).
2. L. Gonzalez-Mariscal *et al.*, Tight junction proteins ZO-1, ZO-2, and occludin along isolated renal tubules. *Kidney Int* **57**, 2386–2402 (2000).
3. M. Rescigno *et al.*, Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. *Nat Immunol* **2**, 361–367 (2001).
4. N. Ogasawara *et al.*, Induction of JAM-A during differentiation of human THP-1 dendritic cells. *Biochem Biophys Res Commun* **389**, 543–549 (2009).
5. A. J. Brown, W. Jessup, Oxysterols and atherosclerosis. *Atherosclerosis* **142**, 1–28 (1999).
6. Y. Son, S. M. Kim, S. A. Lee, S. K. Eo, K. Kim, Oxysterols induce transition of monocytic cells to phenotypically mature dendritic cell-like cells. *Biochem Biophys Res Commun* **438**, 161–168 (2013).

7. S. M. Kim *et al.*, 27-Hydroxycholesterol and 7 α -hydroxycholesterol trigger a sequence of events leading to migration of CCR5-expressing Th1 lymphocytes. *Toxicology and applied pharmacology* **274**, 462–470 (2014).
8. Y. Son, B. Y. Kim, S. K. Eo, Y. C. Park, K. Kim, Dexamethasone Suppresses Oxysterol-Induced Differentiation of Monocytic Cells. *Oxid Med Cell Longev* 2016, 2915382 (2016).
9. H. R. Cho *et al.*, 7 α -Hydroxycholesterol induces monocyte/macrophage cell expression of interleukin-8 via C5a receptor. *PLoS One* **12**, e0173749 (2017).
10. J. M. Hayden *et al.*, Induction of monocyte differentiation and foam cell formation in vitro by 7-ketocholesterol. *Journal of lipid research* **43**, 26–35 (2002).
11. H. R. Cho *et al.*, 7-Oxygenated cholesterol molecules differentially affect the expression of zonula occludens-1 in vascular smooth muscle cells and monocyte/macrophage cells. *Biochem Biophys Res Commun* **497**, 521–526 (2018).
12. Y. Son, B. Y. Kim, Y. C. Park, K. Kim, Diclofenac Inhibits 27-hydroxycholesterol-induced Differentiation of Monocytic Cells into Mature Dendritic Cells. *Immune Netw* **17**, 179–185 (2017).
13. Y. Son *et al.*, Cyclosporin A inhibits differentiation and activation of monocytic cells induced by 27-hydroxycholesterol. *Int Immunopharmacol* **69**, 358–367 (2019).
14. J. C. Herve, M. Derangeon, D. Sarrouilhe, N. Bourmeyster, Influence of the scaffolding protein Zonula Occludens (ZO)s on membrane channels. *Biochimica et biophysica acta* **1838**, 595–604 (2014).
15. L. Gonzalez-Mariscal, H. Gallego-Gutierrez, L. Gonzalez-Gonzalez, C. Hernandez-Guzman, ZO-2 Is a Master Regulator of Gene Expression, Cell Proliferation, Cytoarchitecture, and Cell Size. *Int J Mol Sci* **20**, (2019).
16. C. T. Capaldo *et al.*, Tight junction zonula occludens-3 regulates cyclin D1-dependent cell proliferation. *Mol Biol Cell* **22**, 1677–1685 (2011).
17. C. J. Gottardi, M. Arpin, A. S. Fanning, D. Louvard, The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. *Proceedings of the National Academy of Sciences of the United States of America* **93**, 10779–10784 (1996).
18. M. S. Balda, K. Matter, The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression. *Embo J* **19**, 2024–2033 (2000).
19. L. Huo *et al.*, Cdc42-dependent formation of the ZO-1/MRCK β complex at the leading edge controls cell migration. *EMBO J* **30**, 665–678 (2011).
20. J. Liu, C. Huang, X. Zhan, Src is required for cell migration and shape changes induced by fibroblast growth factor 1. *Oncogene* **18**, 6700–6706 (1999).
21. R. J. Cain, A. J. Ridley, Phosphoinositide 3-kinases in cell migration. *Biol Cell* **101**, 13–29 (2009).
22. S. Tanimura, K. Takeda, ERK signalling as a regulator of cell motility. *J Biochem* **162**, 145–154 (2017).

Figures




Figure 1

The ZO-1 expression following treatment with 27OHChol.

THP-1 cells (1×10^6 cells/60-mm culture dish) were treated for 48 h with 5 $\mu\text{g/ml}$ of cholesterol or 2.5 $\mu\text{g/ml}$ of 27OHChol. (A) The transcript levels of ZO-1 were assessed using RT-PCR and real-time PCR. The data are expressed as the mean \pm SD ($n = 3$ replicates/group). *** $P < 0.01$ vs. control. (B) ZO-1 was analyzed using Immunoblot. The results are representative of three independent experiments. (C) ZO-1 was labeled with a green-fluorescent dye, and the nuclei were counterstained with DAPI. The fluorescence was visualized via confocal microscopy. (D) After immunostaining ZO-1, the cells were analyzed by flow cytometry. The results are representative of three independent experiments.




Figure 2

Effects of 27OHChol concentrations on the ZO-1 expression.

Monocytic cells were stimulated with the indicated concentrations of 27OHChol for 48 h. (A) The transcript levels of the ZO-1 gene were analyzed using quantitative RT-PCR and real-time PCR. The data are expressed as the mean \pm SD (n = 3 replicates/group). *** P < 0.01 vs. control. (B) The proteins harvested from the cells were analyzed by Western blot to detect ZO-1. (C) The cells were immunostained with antibodies against ZO-1 and analyzed by flow cytometry. The results are representative of three independent experiments.




Figure 3

Time-course analyses of the ZO-1 expression following treatment with 27OHChol.

THP-1 monocytic cells were stimulated for the indicated durations of time with 2.5 µg/ml of 27OHChol. (A) The ZO-1 transcript levels were analyzed using RT-PCR and real-time PCR. The data are expressed as the mean ± SD (n = 3 replicates/group). ****P* < 0.01 vs. control; **P* < 0.1 vs. control. (B) The ZO-1 protein was detected via Western blot analysis using cell lysates. (C) The cells were immunostained with antibodies against ZO-1 and analyzed by flow cytometry. The results are representative of three independent experiments.

Figure 4

Effects of BFA on the 27OHChol-induced ZO-1 expression.

THP-1 cells (1×10^6 cells/60-mm culture dish) were treated for 48 h with 10 µg/ml of BFA and 2.5 µg/ml of 27OHChol. (A) The expressed protein of ZO-1 on cell surface was harvested with Pierce™ Cell Surface Protein Isolation Kit, and the isolated protein was analyzed using Western blot. The results are representative of three independent experiments. (B) ZO-1 was labeled with a green-fluorescent dye, and the nuclei were counter-stained with DAPI. The fluorescence was visualized via confocal microscopy. The results are representative of three independent experiments.

Figure 5

Effects of kinase inhibitors on the 27OHChol-induced ZO-1 expression.

THP-1 cells (1×10^6 cells/60 mm culture dish) were treated for 2 h with the indicated inhibitors (10 µM each) and stimulated for 48 h with 2.5 µg/ml of 27OHChol. (A) The levels of ZO-1 transcripts were analyzed using RT-PCR and real-time PCR. The data are expressed as the mean ± SD (n = 3 replicates/group). ****P* < 0.01 vs. control; ###*P* < 0.01 vs. 27OHChol; #*P* < 0.1 vs. 27OHChol. (B) Total proteins obtained from the cells were analyzed via Western blot to detect ZO-1. (C) The ZO-1 protein on the cell surfaces was analyzed by flow cytometry. (D) ZO-1 was labeled with a green-fluorescent dye, and the nuclei were counter-stained with DAPI. The fluorescence was visualized via confocal microscopy. The results are representative of three independent experiments.




Figure 6

Effects of Dx on the 27OHChol-induced ZO-1 expression.

THP-1 cells were stimulated with 2.5 μg/ml of 27OHChol in the presence of 0.01, 0.1, and 1 μM dexamethasone (Dx) for 48 h. (A) The levels of ZO-1 transcripts were analyzed by RT-PCR and quantitative real-time PCR. *** $P < 0.01$ vs. control; ### $P < 0.01$ vs. 27OHChol; # $P < 0.1$ vs. 27OHChol. (B)

Proteins harvested from the cells were analyzed via Western blot to detect ZO-1. (C) The cells, treated with 270HChol and indicated concentration of Dx, were immunostained with fluorescence-conjugated antibodies against ZO-1 and analyzed by flow cytometry. (D) After ZO-1 immunostaining (green fluorescence) and DAPI staining (blue fluorescence), the cells were visualized via confocal microscopy. The results are representative of three independent experiments.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarydataare.docx](#)